Navigation Links
Supplemental New Drug Application Submitted to FDA for NUCYNTA® ER (Tapentadol) Extended-Release Tablets for Diabetic Peripheral Neuropathic Pain
Date:10/31/2011

us tasks such as driving a car or operating machinery. This is to be expected especially at the beginning of treatment, at any change of dosage as well as in combination with alcohol or tranquilizers.
  • NUCYNTA® has not been systematically evaluated in patients with a seizure disorder, and such patients were excluded from clinical studies. NUCYNTA® should be prescribed with care in patients with a history of a seizure disorder or any condition that would put the patient at risk of seizures.
  • The development of a potentially life-threatening serotonin syndrome may occur with use of SNRI products, including NUCYNTA®, particularly with concomitant use of serotonergic drugs such as SSRIs, SNRIs, TCAs, MAOIs and triptans, and with drugs which impair metabolism of serotonin (including MAOIs). Serotonin syndrome may include mental-status changes (eg, agitation, hallucinations, coma), autonomic instability (eg, tachycardia, labile blood pressure, hyperthermia), neuromuscular aberrations (eg, hyperreflexia, incoordination) and/or gastrointestinal symptoms (eg, nausea, vomiting, diarrhea).
  • Withdrawal symptoms may occur if NUCYNTA® is discontinued abruptly. These symptoms may include: anxiety, sweating, insomnia, rigors, pain, nausea, tremors, diarrhea, upper respiratory symptoms, piloerection, and rarely, hallucinations. Withdrawal symptoms may be reduced by tapering NUCYNTA®.
  • Pregnancy Category C. There are no adequate and well-controlled studies of NUCYNTA® in pregnant women. NUCYNTA® should be used during pregnancy ONLY if the potential benefit justifies the potential risk to the fetus. NUCYNTA® is not recommended for use in women during and immediately prior to labor and delivery. Neonates whose mothers have been taking NUCYNTA® should be monitored for respiratory depression. NUCYNTA® should not be used during breastfeeding.
  • NUCYNTA® is not recommended in patients with severe renal or hepatic impairme
    '/>"/>

  • SOURCE Janssen Pharmaceuticals Research & Development
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

    Related medicine technology :

    1. Abbott Receives Supplemental FDA Approval for its Best-in-Class in Sensitivity RealTime HIV-1 Viral Load Test
    2. ORENCIA(R) (abatacept) Supplemental Biologics License Application for Juvenile Idiopathic Arthritis Accepted by FDA for Filing and Review
    3. FDA Accepts Wyeths Supplemental New Drug Application for Tygacil for the Treatment of Patients with Community-Acquired Pneumonia
    4. Supplemental New Drug Application for PREZISTA(TM) Submitted to U.S. Food and Drug Administration
    5. Lilly Submits Cymbalta(R) Supplemental New Drug Application for Chronic Pain to U.S. Food and Drug Administration
    6. CTI to Meet With the FDA to Discuss Filing of a Supplemental Biologics License Application for Zevalin(R)
    7. Anesiva Announces FDA Approval of Supplemental New Drug Application to Expand Zingo(TM) Indication
    8. FDA Grants Priority Review of a Supplemental Biologics License Application for Cinryze(TM) C1 Inhibitor (Human) as Treatment for Acute Attacks of Hereditary Angioedema (HAE)
    9. Cephalon Submits NUVIGIL Supplemental New Drug Application for the Treatment of Excessive Sleepiness Associated with Jet Lag Disorder
    10. Sanofi Pasteur Submits Supplemental Application for A(H1N1) Pandemic Vaccine to U.S. FDA
    11. Cephalon Announces that FDA Grants Priority Review of its Supplemental New Drug Application for NUVIGIL as a Treatment for Excessive Sleepiness Associated with Jet Lag Disorder
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:8/1/2014)... /PRNewswire-iReach/ -- DeepResearchReports.com adds "2014 Deep Research Report ... "2014 Deep Research Report on Global and China ... database. Photo - http://photos.prnewswire.com/prnh/20140731/132164 ... on Global and China Potassium Nitrate  Industry" is ... China and Global Potassium Nitrate ...
    (Date:7/31/2014)... , July 31, 2014  According to data released ... the 2015 average monthly Medicare Part D premium is ... lower than was originally projected, the Pharmaceutical Care Management ... program continues to be a bright spot in American ... in each region and using cutting edge, cost-saving tools ...
    (Date:7/31/2014)... Surgical Company (NASDAQ: STAA ) a leading ... systems for the eye today reported revenue for the ... a 10% increase over $18.2 million reported for the ... revenues grew 11% during the second quarter of 2014 ... of foreign currency exchange reduced sales by $0.1 million ...
    Breaking Medicine Technology:Potassium Nitrate Market & Tricalcium Phosphate Industry Analysis for Global & China Regions 2Potassium Nitrate Market & Tricalcium Phosphate Industry Analysis for Global & China Regions 3Potassium Nitrate Market & Tricalcium Phosphate Industry Analysis for Global & China Regions 4Potassium Nitrate Market & Tricalcium Phosphate Industry Analysis for Global & China Regions 5STAAR Surgical Reports 10% Second Quarter Revenue Growth 2STAAR Surgical Reports 10% Second Quarter Revenue Growth 3STAAR Surgical Reports 10% Second Quarter Revenue Growth 4STAAR Surgical Reports 10% Second Quarter Revenue Growth 5STAAR Surgical Reports 10% Second Quarter Revenue Growth 6STAAR Surgical Reports 10% Second Quarter Revenue Growth 7STAAR Surgical Reports 10% Second Quarter Revenue Growth 8STAAR Surgical Reports 10% Second Quarter Revenue Growth 9STAAR Surgical Reports 10% Second Quarter Revenue Growth 10STAAR Surgical Reports 10% Second Quarter Revenue Growth 11STAAR Surgical Reports 10% Second Quarter Revenue Growth 12STAAR Surgical Reports 10% Second Quarter Revenue Growth 13STAAR Surgical Reports 10% Second Quarter Revenue Growth 14STAAR Surgical Reports 10% Second Quarter Revenue Growth 15STAAR Surgical Reports 10% Second Quarter Revenue Growth 16STAAR Surgical Reports 10% Second Quarter Revenue Growth 17STAAR Surgical Reports 10% Second Quarter Revenue Growth 18STAAR Surgical Reports 10% Second Quarter Revenue Growth 19STAAR Surgical Reports 10% Second Quarter Revenue Growth 20STAAR Surgical Reports 10% Second Quarter Revenue Growth 21STAAR Surgical Reports 10% Second Quarter Revenue Growth 22STAAR Surgical Reports 10% Second Quarter Revenue Growth 23STAAR Surgical Reports 10% Second Quarter Revenue Growth 24STAAR Surgical Reports 10% Second Quarter Revenue Growth 25STAAR Surgical Reports 10% Second Quarter Revenue Growth 26STAAR Surgical Reports 10% Second Quarter Revenue Growth 27STAAR Surgical Reports 10% Second Quarter Revenue Growth 28STAAR Surgical Reports 10% Second Quarter Revenue Growth 29STAAR Surgical Reports 10% Second Quarter Revenue Growth 30STAAR Surgical Reports 10% Second Quarter Revenue Growth 31
    ... (NYSE-Amex: NBS ) today announced that it intends to ... an underwritten public offering. All of the shares and warrants in ... to market conditions, and there can be no assurance as to ... the actual size or terms of the offering. The shares will ...
    ... Ohio, July 18, 2011 BioTech Medical, Inc. announces the ... Dental Chair Pad and Head Cushion to its ... "There isn,t a day that goes by that our ... Tippey, Director of Medical Operations for BioTech Medical, Inc.  "We ...
    Cached Medicine Technology:NeoStem Announces Proposed Public Offering of Common Stock 2NeoStem Announces Proposed Public Offering of Common Stock 3
    (Date:8/1/2014)... The Multiple System Atrophy Coalition, a growing ... and families affected by the neurological disorder Multiple System Atrophy ... Coste, TX to its Board of Directors. , Sharon was ... Sutton. He was diagnosed officially with MSA in 2010 and ... family. Like many others with this rare disorder it took ...
    (Date:8/1/2014)... WA (PRWEB) August 01, 2014 Blindness is ... be argued that the scientists of today, despite well-meaning efforts, ... to providing a definite treatment for reversing blindness that does ... that sense, this is where alternative medicine takes the “slack” ... rely on expensive treatments or harmful surgeries. , Alternative ...
    (Date:8/1/2014)... 01, 2014 Narrow networks that ... and employers effective options to trim pharmacy costs ... that they can enhance formulary compliance and achieve ... report that nearly all PBMs now include a ... proposals. The Aug. 12 webinar from Atlantic ...
    (Date:8/1/2014)... (PRWEB) August 01, 2014 AAGL, ... gynecologic endoscopic surgery, is pleased to announce a ... the United States and Europe, which strongly recommends ... to surgeons an endoscopic dry lab for training ... their endoscopic surgery skills. , Endoscopy is the ...
    (Date:8/1/2014)... Millions of women suffer with lipedema, ... in some cases the arms, causing an abnormal accumulation ... million women in the U.S. alone are affected. With ... pain, embarrassment and discomfort caused by lipedema, it’s remarkable ... unaware that this is a disease,” says Dr. David Greuner, ...
    Breaking Medicine News(10 mins):Health News:Sharon Kramer Sutton, 30 Year Veteran of Rare Disease Advocacy, Appointed to Multiple System Atrophy Coalition Board of Directors 2Health News:Sharon Kramer Sutton, 30 Year Veteran of Rare Disease Advocacy, Appointed to Multiple System Atrophy Coalition Board of Directors 3Health News:The Miracle Cure Review | The Unbeatable Secret to Reversing Any Vision Problem – Vinamy.com 2Health News:Atlantic Information Services Webinar to Offer Health Plan, Employer Strategies for Implementing Narrow Pharma Networks 2Health News:AAGL Announces It Has Joined With Other Medical Societies to Encourage Hospitals Teaching Endoscopic Surgery to Establish Simulator Labs for Training 2Health News:Lipedema Centers Works With Insurers To Gain Coverage For Lipedema Treatment 2
    ... needed for transition to adult health care , , TUESDAY, ... help and information when they approach adulthood to ensure they ... , The study, led by Peter Scal of the University ... arthritis received counseling on issues such as obtaining health insurance ...
    ... Drain NEW YORK, Jan. 13 New York Blood ... City, Long Island, Hudson Valley and New Jersey) have ... demand for blood (needed for emergency care and surgery) ... donation have been below forecast. Blood supplies have ...
    ... shows a visitor photos she,s taken and can see ... than 20 years after Goldring, a senior fellow at MIT,s ... a "seeing machine" that can allow some people who are ... face of a friend and much more. , The team ...
    ... Physician AccessSUNNYVALE, Calif., Jan. 13 Pathwork Diagnostics, ... Pathwork(R) Tissue of Origin Test that has the ... This molecular diagnostic test, which aids in the ... available as a service through the CLIA-certified Pathwork ...
    ... (January 13, 2009) The American Journal of ... and healthcare publications of 2008 with an announcement today ... in 15 separate categories appear in the journal,s January ... variety of controversial consumer health topics and nursing industry ...
    ... FERNANDINA BEACH, Fla., Jan. 13 Zassi Medical,Evolutions(R), ... history of,innovation and development, today announced the launch ... efficiencies to the medical,device industry by streamlining diligence, ... participants with an exclusive array of,intelligent Web-based applications. ...
    Cached Medicine News:Health News:Blood Emergency: Blood Supply Tips Into Danger Zone 2Health News:Blood Emergency: Blood Supply Tips Into Danger Zone 3Health News:Blood Emergency: Blood Supply Tips Into Danger Zone 4Health News:Blood Emergency: Blood Supply Tips Into Danger Zone 5Health News:MIT develops camera for the blind 2Health News:Pathwork Diagnostics Launches Version of Its Tissue of Origin Test for FFPE Specimens 2Health News:Pathwork Diagnostics Launches Version of Its Tissue of Origin Test for FFPE Specimens 3Health News:American Journal of Nursing announces 2008 Book of the Year Awards 2Health News:Zassi Medical Evolutions Launches New Online Company That Uses 'Business DNA' to Deliver Advanced Discovery, Collaboration, and Business Intelligence Tools to the Medical Device Industry 2Health News:Zassi Medical Evolutions Launches New Online Company That Uses 'Business DNA' to Deliver Advanced Discovery, Collaboration, and Business Intelligence Tools to the Medical Device Industry 3
    Series I Small Joint Arthroscopy Hand Instruments feature small yet durable instruments specifically designed for small joint arthroscopy. They are available in a variety of low profile styles: strai...
    Series I Small Joint Arthroscopy Hand Instruments feature small yet durable instruments specifically designed for small joint arthroscopy. They are available in a variety of low profile styles: strai...
    Low-profile, hand-held instrument....
    Low-profile, hand-held instrument....
    Medicine Products: